Welcome, Guest. Please login or register.
September 21, 2023, 04:29:53 am

Login with username, password and session length

  • Total Posts: 55101
  • Total Topics: 4848
  • Online Today: 77
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 38
Total: 38


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Providing Naloxone to People Who Inject Drugs During Hep C Care Drives Up Use  (Read 3316 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Providing naloxone to people who inject drugs (PWID) as part of their medical care for hepatitis C virus (HCV) drives up use of the opioid overdose reversal drug within the larger PWID community, the National AIDS Treatment Advocacy Project (NATAP) reports.

Researchers from the University of Maryland presented findings from the single-center ANCHOR study at the IDWeek meeting in Washington, DC, earlier this month. The study is assessing HCV treatment with Epclusa (sofosbuvir/velpatasvir) among PWID. Clinicians also offer participants the opportunity to receive the medication-assisted treatment with buprenorphine to treat opioid use disorder as well as pre-exposure prophylaxis (PrEP) against HIV.

For more...


© 2023 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.